RecruitingNot ApplicableNCT05460780
First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer
First-in-human Study of MATTISSE® Tissue Engineering Chamber in Adult Female After Total Mastectomy for Breast Cancer in Immediate or Delayed 2-stage Tissue Expander Reconstruction or Conversion from Implant-based to Autologous Reconstruction
Sponsor
Quanta Medical
Enrollment
50 participants
Start Date
Jul 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a first in human, two-stage single arm non-comparative study of safety and performance. The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria43
- Criteria related to pathology:
- Female patient over 18 Years old
- Patient who required autologous breast reconstruction:
- Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer
- Breast reconstruction after unilateral preventive total mastectomy
- or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation
- or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it.
- For patient with active cancer: Patient with early-stage cancer (stage 0, I or II, with tumor size \< 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site
- Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction.
- Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting.
- Patient medically fit for surgery without significant comorbidities
- Breast cup-size less than D
- Body mass index \>20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment
- Adequate hematopoietic functions
- Criteria related to population:
- Subjects who have given free, informed and written consent to participate in the study;
- Patient able to answer questionnaires, able to communicate in the language of the study country;
- Subjects affiliated to a social security schema or entitled to a social security scheme.
- Pathology related criteria:
- Patient undergoing bilateral reconstruction
- Patient undergoing bilateral preventive mastectomy
- Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation
- Previous history of radiotherapy on the breast area or on the flap donor site
- Previous history of breast or axillary surgery that does not allow fat flap dissection
- Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI
- Body mass index \>30 kg/m2
- Taking medication for weight loss at the time of inclusion visit
- Presence of major medical conditions that may compromise patient's health and healing
- Diabetes and a history of gestational diabetes
- Active smoking
- Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease)
- Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination
- Allergy to anesthetics or contrast media
- Immunocompromised patient (HIV) or patient used immunosuppressants
- Population related criteria
- Pregnant patient
- or breastfeeding patient or woman who has nursed a child three months within inclusion
- Participation in a clinical trial in the 3 months prior to the initial visit
- Predicted unavailability during study.
- Patient deprived of liberty or under guardianship.
- Patient unable to give consent
- Medical device related criteria
- Allergy to any of the components of the medical device.
Exclusion Criteria3
- Positive or suspicious extemporaneous sentinel node biopsy
- Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler
- Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment
Interventions
DEVICEMATTISSE TEC
Tissue engineering chamber MATTISSE
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05460780
Related Trials
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT065076184 locations
GammaPod Registry and Quality of Life Nomogram
NCT035622734 locations
Cognitive Rehabilitation Following Breast Cancer Treatment
NCT065450451 location
Guided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy
NCT065520911 location
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
NCT072421182 locations